Skip Navigation
A statewide network led by MUSC
banner image for SC2


Our Research Team

Brandi Day: Research Coordinator
Ashley Green: Research Coordinator
Karen Hawkins: Research Nurse
Joannie Hayes: Research Coordinator
​Carly Lauer: Research Assistant
Emily Warner: Sickle Cell Research Program Manager
Katherine Williams-Turner: Sickle Cell State Coordinator

Clinical Trials

For more information or to see if you are eligible for a clinical trial today contact Emily Warner at 843-876-8614 or

  • Calypso: A Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an improved Deferasirox Formulation (granules) in Pediatric Patients with Iron Overload. 
  • FIRST: Phase III study to evaluate the use of a new iron chelator (FERRIPROX) for patients with sickle cell disease and iron overload
  • GBT440-025: Phase II, Open-label, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease and Severe Anemia.
  • HESTIA 1: Phase I/II study to evaluate the use of Ticagrelor for the prevention of pain and complications in children with sickle cell anemia
  • HGB206: Phase I gene therapy and autologous transplant study
  • Point of care: We are working with Biomedomics to evaluate a new point of care test, Sickle SCANTM to improve the diagnosis of patients with sickle cell disease at the bedside
  • Reset Trial: Phase III study for children and adults to evaluate the use of a new IV medication (Rivapansel) to decrease pain and hospitalization in patients with sickle cell disease
  • SGHY-001: Phase I, Open-label Safety Study of SANGUINATE Infusion in Patients with Acute Severe Anemia who are unable to receive Red Blood Cell Transfusion. 
  • STRIDE: A bone marrow transplant study to evaluate outcomes in patients with sickle cell disease undergoing bone marrow transplant compared to standard of care
  • STAR: We are part of a large group of other centers specializing in bone marrow transplant for children and adults with sickle cell disease

Departmental and Interdisciplinary Research Resources

South Carolina Clinical and Translational Research Institute (SCTR)
The Medical University of South Carolina established the South Carolina Clinical and Translational Research Institute (SCTR) in 2006 in response to the NIH Clinical and Translational Science Award (CTSA) Program, aimed at transforming approaches to research and discovery implementation. The main thrust of the CTSA Program is to catalyze the development of interdisciplinary research initiatives to accelerate the translation of discoveries into improved therapies and clinical practice while breaking down programmatic boundaries. MUSC received NIH funding for the SCTR in July 2009; the present application requests renewed support for the next five year period. Multiple cores currently operate under the SCTR umbrella, including:

  • Biomedical Informatics
  • Community Engagement
  • Biostatistics & Epidemiology
  • Novel Clinical & Translational Methodologies
  • Regulatory Knowledge and Support
  • Research Ethics
  • SUCCESS Center & Research Toolkit
  • Training and Education
  • Translational Technologies & Resources